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Abstract 
 
Background: 
Acute fatty liver of pregnancy is a rare condition and there has been no attempt to 
correlate clinical diagnostic criteria and histologically proven acute fatty liver of pregnancy 
(AFLP). The aim of this study was to assess the accuracy of the recommended criteria in 
diagnosing acute fatty liver of pregnancy that was proven by histology. 
 
Methods: 
A retrospective study of patients with acute liver failure in the third trimester of 
pregnancy was conducted. The patient group included all the patients who had undergone a liver 
biopsy for a suspicion of pregnancy related liver dysfunction between 1998 and 2008 and an 
additional group of patients in whom there was another defined cause of acute liver failure in 
whom no biopsy was attempted. Liver histology was reviewed by a single hepato-pathologist. 
The patients were classified into three groups – Group A - those in whom the liver biopsy proved 
that the condition was AFLP, Group B - those in whom the liver biopsy was indeterminate or 
inconsistent and Group C - those in whom an alternate explanation for liver failure was defined 
by tests other than biopsy. We tested the accepted clinical criteria for diagnosis in these three 
groups. 
  
Results:   
There were 17 patients in Group A, 7 patients in Group B and 11 patients in Group C. 
Using Group A and C to measure sensitivity and specificity we found that the diagnostic criteria 
were 100% sensitive but had a low specificity. The criteria were also positive in a proportion of 
the small number of cases in Group B – the indeterminate group.  
 
Conclusion: 
The diagnostic criteria are an accurate way of diagnosing acute fatty liver of pregnancy 
with a 100% negative predictive value. Therefore these criteria are useful in making the 
diagnosis but do not exclude other causes, which must always be scrupulously excluded. 
 
Key words:  
Acute fatty liver of pregnancy, AFLP, HELLP syndrome, pre-eclampsia. 
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Introduction 
 
 
Abnormal liver tests occur in 3%-5% of pregnancies, with many potential causes. 
Although relatively uncommon, any liver disease can occur coincidentally in the pregnant patient 
and pregnancy may occur in a patient with underlying chronic liver disease. However, most liver 
dysfunction in pregnancy is pregnancy-related and due to one of the 5 liver diseases unique to 
the pregnant state—hyperemesis gravidarum (HG), intrahepatic cholestasis of pregnancy (ICP), 
pre-eclampsia, HELLP syndrome, and acute fatty liver of pregnancy (AFLP)1. 
These conditions are associated with pregnancy itself, and each has a characteristic timing in 
relation to the trimesters of pregnancy: HG in the first trimester, ICP in the second half of 
pregnancy, and the other 3 in the third trimester. 
Other rare conditions that occur more commonly during pregnancy are - Budd- Chiari syndrome, 
hepatic haematoma and rupture, hepatic infarction and primary hepatic malignancy2. Common 
causes in each group are listed in Table 1. 
Of all pregnancy related liver diseases, pre-eclamptic liver dysfunction, HELLP syndrome and 
AFLP are the life threatening causes of liver failure. There is a considerable overlap in the 
clinical presentation of these syndromes.  
Acute fatty liver of pregnancy (AFLP) is a relatively rare and incompletely understood illness, 
occurring in 3rd trimester and causing considerable maternal and perinatal mortality. The delay in 
diagnosis, due to the initial non-specific symptoms, should be avoided. Early termination of 
pregnancy results in rapid resolution of the illness and so timely diagnosis is of primary 
importance. The gold standard for diagnosis of AFLP is liver biopsy, which is difficult in an 
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acute setting3. The diagnosis is usually based on clinical criteria which has been proposed by 
Ch’ng et al4, and has been recently validated prospectively by Knight et al5. None of these 
studies had liver biopsy as a pre-requisite. 
AFLP has only very rarely been reported from India, and the exact incidence or prevalence in 
Indian population is not known6-9.   
The present study was conducted to evaluate the accuracy of the diagnostic criteria proposed by 
Ch’ng et al (Swansea criteria) to diagnose biopsy proven acute fatty liver of pregnancy. The 
clinical features, laboratory and histology parameters and outcome of patients with AFLP were 
also studied.  
 
 
Coincidental to pregnancy Underlying chronic liver 
disease 
Diseases unique to 
pregnancy 
Viral Hepatitis Chronic Hepatitis B/ C Hyperemesis gravidarum, 
Gall stones Auto-immune hepatitis Intrahepatic cholestasis of 
pregnancy (ICP), 
Drugs Primary sclerosing cholangitis Pre-eclampsia, 
Sepsis Wilson Disease HELLP syndrome 
Budd Chiari Syndrome Primary biliary cirrhosis Acute fatty liver of pregnancy 
(AFLP) 
 Cirrhosis  
  
 
Table 1:  Diagnostic categories of liver disease in pregnancy1 
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Aim 
 
 
1. To assess the accuracy of Swansea criteria for acute fatty liver of pregnancy in 
diagnosing biopsy proven acute fatty liver of pregnancy. 
 
2. Case series of acute fatty liver of pregnancy with detailed description of clinical features, 
laboratory parameters, histology findings and outcome. 
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Review of literature 
 
History : 
Acute fatty liver of pregnancy (AFLP) is a maternal liver disease unique to pregnancy. It 
was first described in 1934 as “yellow acute atrophy of the liver”10 and was described as a 
specific clinical entity in 194011. Since then there has been detailed research with description of 
the histology features and probable pathogenetic mechanisms involved. 
The research has been hampered with relative rarity of the disease and especially from India 
where even large series on acute liver failure in pregnancy, has not identified it as a major cause 
of the illness12,13. 
 
Epidemiology of AFLP : 
The epidemiologic studies are hampered by the rarity of the condition and the estimate of 
incidence and prevalence varies depending on the study design. Existing literature consists 
predominantly of small hospital-based case series or historical cohorts identified retrospectively 
over a number of years14,15. Both these study types have limitations and thus the incidence 
estimates from these studies vary widely between 1 in 900 and 1 in 16 000 deliveries4,7,16. A 
recent prospective study in UK derived a population based incidence of 1 in 20,000 births5.  
Indian data is scarce but a prospective hospital based study by Rathi et al, estimated an incidence 
of ~ 1 in 4000 deliveries7.  
It affects women of all ages and races and there is no distinctive epidemiologic feature 
that has been related to geographic areas or ethnic groups3. The onset of AFLP is between the 
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30th and 38th wk of gestation although an early occurrence at 26 wk has been reported. There 
are rare reports of AFLP diagnosis in the second trimester17. It is more frequent in primaparous 
than multiparous women but can occur even after multiple uneventful pregnancies. Several 
reports have documented recurrence of AFLP in subsequent pregnancies18. 
Maternal case fatality estimates range between 12% and 18%, and neonatal mortality estimates 
range from 7% to 58%5. Indian study by Devarbhavi et al, demonstrated a maternal and perinatal 
mortality of 41% and 53% respectively in patients with pregnancy related liver disease9.  
 
Pathogenesis of AFLP3 : 
The pathogenesis of AFLP is still elusive and details are still not completely uncovered. 
Recent molecular advances suggest that it may result from mitochondrial dysfunction, and there 
has been a strong association between AFLP and deficiency of the enzyme long-chain 3-
hydroxyacyl-CoA dehydrogenase (LCHAD) in the fetus, a disorder of mitochondrial fatty acid 
beta-oxidation. 
 
Mitochondrial Fatty acid oxidation (Figure 1.19) : 
 The β-oxidation of fatty acids is the major source of energy for skeletal muscle and the 
heart, while the liver oxidizes fatty acids primarily under the conditions of prolonged fasting, 
during illness, and at periods of increased muscular activity.  
Mitochondrial ß-oxidation of fatty acids is a complex process that consists of multiple transport 
steps and four enzymatic reactions resulting in the sequential removal of two-carbon, acetyl-
coenzyme A units. The 4 reactions in steps in ß-oxidation spiral are demonstrated in Figure 1. 
Each step has separate sets of enzymes.  
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For long chain length fatty acids, the last three steps are mediated by an enzyme complex called 
mitochondrial trifunctional protein (MTP). MTP, also known as trifunctional protein (TFP), is a 
hetero-octamer of 4α- and 4ß- subunits. The α-subunit amino-terminal domain contains the long 
chain 3-enoyl-CoA hydratase enzymatic activity while the LCHAD enzymatic activity resides in 
the carboxy terminal domain. The ß-subunit has the long-chain 3-ketoacyl-CoA thiolase 
enzymatic activity. Both subunit genes, HADHA and HADHB, have been localized to 
chromosome 2p2320. 
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Figure 1: Overview of mitochondrial ß-oxidation of fatty acids.  
 
CPT-1, carnitine palmitoyltransferase-1; CPT-2, carnitine palmitoyltransferase-2; CT, 
carnitine/acyl-carnitine translocase; ETF, electron transport flavoprotein; LCAD, long-
chain acyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; SCAD, 
shortchain acyl-CoA dehydrogenase; TCA, tricarboxylic acid cycle; VLCAD, very long-
chain acyl-CoA dehydrogenase 
 
 
 
 
 
 
Fatty acid oxidation disorders : 
 
Fatty acid oxidation disorders have become an important group of inherited metabolic 
disorders characterized by a wide array of clinical presentations and as important causes of 
pediatric morbidity and mortality. LCHAD deficiency was first described in 1989 and MTP 
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deficiency in 1992. These defects, if unrecognized can be cause of sudden infant death syndrome 
(SIDS).  
 
Mitochondrial trifunctional protein defects : 
Human defects in the MTP complex are recessively inherited and cause either isolated 
LCHAD deficiency, with normal or partially reduced thiolase and hydratase activity, or complete 
MTP deficiency with markedly reduced activity of all 3 enzymes. In the literature, the majority 
of patients reported have been described as having isolated LCHAD deficiency21.  
G1528C mutation in exon 15 of the α-subunit which alters amino acid 474 from glutamic acid to 
glutamine (E474Q), results in isolated LCHAD deficiency and was strongly associated with 
AFLP in mothers and the infant were at risk of hypoketotic hypoglycemia and fatty liver21. This 
mutation blocks ß-oxidation and results in accumulation of 3-hydroxy fatty acid metabolites.  
Other mutations in the gene caused deficiency of all the three components of MTP and were not 
associated with AFLP in mothers. 
 
Fetal mitochondrial trifunctional protein defects and maternal liver disease :  
Schoeman et al were the first to notice the relationship between fetal fatty acid oxidation 
disorder and maternal fatty liver of pregnancy22. Since then several studies document strong and 
somewhat unique causative association between fetal MTP defects and AFLP23,24. 
Ibdah et al, in their study on maternal liver disease in infants with MTP defects, concluded that 
when carrying an LCHAD-deficient fetus, there is a 79% chance that the pregnancy will be 
complicated by AFLP or HELLP syndrome21.  
In a subsequent study, Yang et al25 evaluated fetal genotypes and pregnancy outcomes in 83 
pregnancies in 35 families with documented pediatric MTP defects. 60% of the mothers carrying 
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the affected fetuses had AFLP or HELLP syndrome, and all women who had the maternal illness 
carried fetuses with isolated long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency25. 
Yang et al26 in another study prospectively screened 27 pregnancies complicated by AFLP and 
81 pregnancies complicated by HELLP syndrome. Out of the 27 women that developed AFLP, 5 
carried fetuses with MTP mutations. Three were homozygous for the G1528C mutation and two 
were compound heterozygotes. None of the children born to the 81 women diagnosed with 
HELLP syndrome carried MTP mutations. This study documents that in approximately one of 
five pregnancies complicated by AFLP, the fetus is LCHAD-deficient.  
This strong association between AFLP and the common G1528C mutation in the fetus is 
significant and hence screening the offspring of women who develop AFLP at birth for this 
mutation can be life saving.  If done early it may identify LCHAD-deficient children before they 
manifest the disease allowing early dietary intervention by institution of a diet low in fat, high in 
carbohydrate, and by substitution of the long chain fatty acids with medium chain fatty acids. In 
addition, it allows genetic counseling for the mothers and prenatal diagnosis in subsequent 
pregnancies, which was shown by Ibdah et al as feasible and useful27.  
 
Possible hypothesis for the association between fetal LCHAD deficiency and acute fatty liver of 
pregnancy :  
The precise mechanism by which an LCHAD-deficient fetus causes AFLP in a 
heterozygote mother is still unclear. The hypothesis is illustrated in Figure 2. The heterozygosity 
of the mother reduces her capacity to oxidize long chain fatty acids. Also there is an increased 
lipolysis and decreased oxidation during stressful conditions- e.g. pregnancy. In the presence of 
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the G1528C mutation, potentially hepatotoxic long chain 3-hydroxyacyl fatty acid metabolites, 
produced by the fetus or placenta28, accumulate in the maternal circulation. 
 
 
 
Figure 2 : Hypothesis illustrating the possible role of fetal and maternal MTP mutations in 
developing acute fatty liver of pregnancy3. 
 
The role of other fatty acid oxidation defects in development of AFLP is not very clear.  There 
have been case reports linking AFLP like disease in mother to fetal deficiency of carnitine 
palmitoyl transferase I (CPT-I)29, SCAD30, and MCAD31.  
Long chain defects were 50 times more likely than controls to develop maternal liver disease and 
short and medium chain defects were 12 times more likely to develop maternal liver disease32. 
Toxic metabolites 
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To conclude, 1 in five patients with AFLP has LCHAD deficiency, emphasizing the importance 
of genetic testing in these patients and their off springs. It also highlights that 80% of the patients 
with AFLP do not have a known cause, and further research is needed to elucidate the other 
possible pathogenetic mechanisms. 
 
Clinical features of AFLP1,2,3,5,7 : 
40%-50% of patients with AFLP are nulliparous, with an increased incidence in twin 
pregnancies32,33. AFLP occurs almost exclusively in the third trimester and very rarely in late 
second trimester. In a few patients, it presents as jaundice in the postpartum period.  
The presentation can vary from asymptomatic to fulminant liver failure. The typical patient has 1 
to 2 weeks of anorexia, nausea and vomiting, headache, and right upper quadrant pain, and is ill-
looking with jaundice, hypertension, edema, ascites, a small liver, and hepatic encephalopathy. 
Polydipsia and skin pruritus were the unusual symptoms16,34. AFLP patients may also present 
with upper gastrointestinal hemorrhage (due to portal hypertension and coagulation 
abnormalities), acute renal failure, sepsis, pancreatitis, hypoglycemia or metabolic acidosis. 
Hepatic encephalopathy tends to occur late in the disease2. 
Intrauterine death may occur. About 50% of patients with AFLP have preeclampsia, and there is 
some overlap with the HELLP syndrome35. 
The initial clinical features are thus very non-specific and it needs a high index of clinical 
suspicion to arrive at an early diagnosis. 
 
Laboratory and radiologic features of AFLP : 
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The features are non-specific and do not help reach a confirmatory diagnosis. 
Aminotransferases vary from near normal to 1000, usually 300- 500 IU/L; bilirubin is usually 
less than 5 mg% but higher in severe or complicated disease. Serum alkaline phosphatase levels 
are mildly elevated but can be as high as 3-4 times normal. 
Other typical abnormalities are normochromic, normocytic anemia, high white blood cell count, 
normal to low platelets, coagulopathy with or without DIC, metabolic acidosis, renal dysfunction 
(often progressing to oliguric renal failure), hypoglycemia, high ammonia, hyperuricemia and 
biochemical pancreatitis1,2,32. In comparison with those with HELLP syndrome, patients with 
AFLP are more likely to show liver failure with coagulopathy, hypoglycemia, encephalopathy, 
DIC, and renal failure1,2,5,34,36. 
Ultrasound, computerized tomography and magnetic resonance imaging have been 
utilized as non-invasive tools for diagnosing AFLP but their value remains limited with false 
negative results being most common. Ultrasound revealed ascites and/or bright liver in only a 
quarter of patients in the prospective study by Knight et al5.A study revealed that computed 
tomography findings were normal in > 50% of patients with AFLP37. Thus in clinical practice, 
the decision to deliver the fetus should not be delayed by the time required to obtain or the 
results of these radiologic examinations2,37. 
 
Pathology of AFLP1,2,38 : 
The presumptive diagnosis of AFLP is made on compatible clinical and laboratory 
features, the need for expeditious therapy and presence of coagulopathy precludes biopsy.  
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A definitive diagnosis is histological—micro vesicular fatty infiltration (free fatty acids) 
predominantly in zones 2 and 3 with lobular disarray and only a mild portal inflammation with 
cholestasis39,40,41.  
Fatty metamorphosis demonstrated as cytoplasmic ballooning (fat droplets <1 µm), discrete 
micro vesicles (2-12 µm); and/ or macro vesicles was the dominant change in the biopsy/autopsy 
specimens of acute fatty liver of pregnancy, in a study by Rolfes et al38. These represented a 
continuum of change with ballooning being present early in the course of the disease. Similarly 
late in the convalescent phase, ballooning may represent mobilization of fat from the liver. 
Ballooning usually represents micro droplets of lipid which are not visible on light microscopy, 
and so an alternative fat stain may be helpful. Fatty metamorphosis may be zonal or pan-acinar.  
The other features noted in this study were – hepatocyte necrosis, mild to moderate cholestasis, 
minimal or no inflammation, extramedullary hematopoiesis and absence of fibrosis. 
Substantial loss of parenchyma is responsible for small size of liver, and prolapse of hepatocytes, 
secondary to necrotizing phlebitis, into hepatic venules leads to portal hypertension. 
The histology can be confused with acute viral hepatitis, more so early in the disease, and also 
with pre-eclampsia in rare cases42. 
Electron microscopy: In patients with cytoplasmic ballooning, non-membrane bound 
lipid droplets were demonstrated in the patients lacking micro vesicular steatosis on light 
microscopy. Mitochondrial abnormalities were also noticed in a minority.  
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Figure 3. : Slide showing typical features of acute fatty liver of pregnancy- diffuse micro 
vesicular steatosis and ballooning (H&E stain). 
 
 
Diagnosis of AFLP : 
The initial presentation of AFLP is usually non-specific. The symptoms, signs and 
laboratory features are not specific enough to diagnose or rule out the possibility of AFLP. The 
radiologic features are also usually not helpful in this aspect. Histology, though is supposed to be 
gold standard, is difficult to obtain in a sick patient with coagulaopathy and ascites1,2,3. Thus the 
diagnosis of acute failure of pregnancy is essentially one of exclusion. It should be suspected in 
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any patient with jaundice with or without acute liver failure in 3rd trimester with no etiology 
evident. The difficulty is in obtaining an etiologic workup at the earliest; esp. in lesser equipped 
centers9.  
Ch’ng et al4 in their study proposed a set of diagnostic criteria for AFLP. The criteria proposed 
were based on the prior retrospective case series on the subject41,43,44. These criteria were 
recently validated in a large prospective study by Knight et al5. These criteria known as 
‘Swansea criteria’, lay down a list of parameters for the diagnosis of various pregnancy related 
liver diseases. These are shown in Table 2.  
These criteria are a mix of various parameters and assume the absence of a contributory etiology. 
Swansea criteria were validated in a recent population based study by Knight et al, and the 
criteria agreed to the clinical diagnosis of the physician. There was no gold standard for the 
diagnosis in this study and it showed only an agreement between clinical judgment and Swansea 
criteria. There has been no study evaluating the accuracy of these criteria against gold standard – 
liver biopsy.  
Secondly, the assumption of negative etiology workup is an important drawback. These set of 
criteria cannot distinguish other etiology of liver failure from AFLP and thus may not be helpful 
in making a decision in emergency setting in a lesser equipped center where a diagnostic workup 
may take time. Till date there has been no study in demonstrating the usefulness of these criteria 
in distinguishing AFLP from other etiologies of ALF in pregnancy. 
 
 
16 
 
AFLP 
Six or more of the following features in the absence of another 
explanation: 
• Vomiting 
• Abdominal pain 
• Polydipsia/polyuria 
• Encephalopathy 
• Elevated bilirubin 
• Hypoglycemia 
• Elevated urate 
• Leucocytosis 
• Ascites or bright liver on ultrasound scan (USS) 
• Elevated transaminases 
• Elevated ammonia 
• Renal impairment 
• Coagulopathy 
• Micro vesicular steatosis on liver biopsy 
 
HELLP syndrome 
• Elevated AST >70 iu/l 
• Low platelet count 100X109/l 
• Hemolysis (lactate dehydrogenase (LDH) >600 U/l). 
Partial HELLP 
syndrome 
• Elevated AST > 40 iu/l 
• Low platelet count <150X109/l 
• Absence or presence of hemolysis. 
 
Pre-eclamptic liver 
dysfunction 
Elevated liver enzymes or bilirubin in the presence of 
hypertension, proteinuria, and edema after 20 weeks of gestation. 
 
Hyperemesis 
gravidarum 
Elevated liver enzymes or bilirubin in the presence of persistent vomiting 
for more than one week during the first or second trimester. 
 
Obstetric cholestasis 
Pruritus with elevated serum transaminases and/or bile acids in the second 
or third trimester. 
 
 
Table 2. : Diagnostic criteria for various pregnancy related liver diseases4. 
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Differential Diagnosis : 
The patient usually presents with jaundice with/ without liver failure in 3rd trimester. The 
differentials to be considered are varied – pregnancy in a patient with pre-existing liver disease, 
incidental liver diseases during pregnancy and pregnancy related liver diseases. The various 
common conditions in these broad differentials is listed in Table 1.  
The history, physical examination, radiologic tests and laboratory parameters usually help in 
diagnosis of an underlying pre-existent chronic liver disease. The other tests- serology for HAV, 
HEV, HBV, HCV, CMV; peripheral smear for malaria parasite, USG for 
choledocholithiasis/hepatic infarct and  serology for scrub typhus/ leptospirosis; are done as 
clinically indicated to differentiate incidental acute liver dysfunction during pregnancy.  
The major other condition that must be excluded is the HELLP syndrome, which is characterized 
by hemolysis, elevated liver enzymes, and a low platelet count. The patients of HELLP usually 
have only mild elevation of liver enzymes, mild hyperbilirubinemia, no DIC/ coagulaopthy, 
normal USG and non-specific liver histology. Moreover patients with HELLP are less likely to 
have the mutatations in fatty acid oxidation pathways26. A large clinical overlap between AFLP 
and HELLP syndrome makes it difficult, even impossible, to differentiate them. However, 
evidence of hepatic insufficiency such as hypoglycemia or encephalopathy is suggestive of 
AFLP.  
In one series of 46 women who developed liver disease during pregnancy severe enough to 
require admission to a liver failure unit, 70% had acute fatty liver and 15% had HELLP 
syndrome45. In the study by Rathi et al7, the majority of patients with liver dysfunction in 3rd 
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trimester were secondary to HELLP/ partial HELLP syndrome. There is a considerable overlap 
between these syndromes and it is often difficult to distinguish between these46. The different 
features of the various pregnancy related liver disease is given in Table 3. There is also a 
considerable overlap between pre-eclampsia and AFLP as well, but the pathogenetic 
mechanisms, and histology features are different.  
The differentiation between various pregnancy related liver diseases is of theoretic importance 
only, as the management is singular – prompt termination of pregnancy. 
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Disorder Gestational age 
at presentation 
Symptoms Specific labs Outcome Treatment 
HG 1st trimester 
Nausea and 
vomiting. 
AST,ALT < 
200 
Benign for 
mother 
and child; 
Likely recurs 
IV fluids 
Thiamine 
Pyridoxine 
Promethazine: 
FDA C 
AFLP 3rd trimester 
Nausea vomit 
abdominal pain 
Progress quickly 
to FHF, 50% 
have eclampsia 
AST,ALT 
>300 
Bilirubin high 
DIC 
Uric acid high 
Maternal 
mortality 30%, 
Fetal mortality up 
to 35%. 
Recurs 
Prompt delivery 
Liver transplant 
if FHF 
IHCP 3rd trimester Pruritus 
GGT> normal 
Bile Acids 
high 
PT normal 
Bilirubin < 5 
AST,ALT<300
Increase maternal 
gallstones related 
disorders 
Risk for fetal 
distress+ 
Often recurs 
Actigall 
Delivery when 
fetal distress is 
imminent 
HELLP 
Beyond 22 
weeks and after 
delivery. 
Abdominal pain 
Mild renal 
failure 
20% progress 
from eclampsia 
Platelets 
<100,000 
Hemolysis, 
DIC 
Maternal 
mortality up to 
3.5% and fetal 
death 6-37 % 
Hepatic rupture is 
associated with 
60% maternal 
mortality 
Likely recurs 
Prompt delivery
 
Table 3. : Features of liver disease unique to pregnancy 
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Management of AFLP : 
The primary treatment of acute fatty liver of pregnancy is prompt delivery, usually 
emergently, after maternal stabilization. There are no reports of recovery before delivery1.  
Delivery is affected usually by caesarean section, but the type of delivery should be based on 
obstetric assessment of likelihood of rapid controlled vaginal delivery in less than 24 hours. 
Vaginal delivery will reduce the incidence of major intra-abdominal bleeding but is best affected 
with an international normalized ratio of less than 1.5 and platelet count of greater than 50,0001. 
Prophylactic antibiotics are recommended to prevent uterine infections1,32. 
The prothrombin time usually starts to normalize shortly thereafter although, in most severe 
cases, there may be many more days of illness requiring maximal supportive management in an 
intensive care unit, including mechanical ventilation because of coma, dialysis for acute renal 
failure, parenteral nutrition because of associated pancreatitis, or even surgery to treat bleeding 
from a preceding cesarean section. 
Maternal stabilization requires glucose infusion and reversal of coagulopathy (e.g., 
administration of fresh frozen plasma, cryoprecipitate, packed red blood cells, and, rarely, 
platelets), as needed. Attention should be paid to the women's overall fluid status; therefore, 
small volumes of cryoprecipitate are often preferable to fresh frozen plasma. Antibiotics 
prophylaxis is to be strongly considered. 
Most severely ill patients recover and have no sequel of the liver disease itself47. However, 
substantial morbidity and mortality can occur. In a population-based study that included 57 
patients with acute fatty liver of pregnancy, one woman required a liver transplant and one 
woman died (case fatality rate of 1.8 percent, 95% CI 0 to 9 percent)5. There were seven deaths 
among 67 infants (perinatal mortality rate of 104 per 1000 births, 95% CI 32 to 203). Other 
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reports have also described patients who required liver transplantation48,49 but it is unlikely to be 
needed with early diagnosis and prompt delivery.  
 
Prognosis and Outcome in patients with AFLP:  
 
Recovery can occur in days or be delayed for months but is complete with no signs of 
chronic liver disease1. 
With advances in supportive management of these patients, the mortality is reduced from almost 
universal to – maternal being 7%-18% and fetal mortality 9%-23%1,50. 
There have been case reports of the recurrence of AFLP in subsequent pregnancies18,51, and 
patients are to be referred to genetics specialist for screening and counseling.  
Newborns of these patients may have fatty acid oxidation defect25-27 and they typically present 
with hypoketotic hypoglycemia, metabolic acidosis, hepatic failure, and cardiomyopathy. Late 
presentations include episodic myopathy, neuropathy, retinopathy, and arrhythmias. Sudden 
unexpected death can occur at any age and can be confused with sudden infant death syndrome52.  
Regarding the infant, screening for LCHAD deficiency should be performed on all babies born 
to mothers with a diagnosis of AFLP. Those who are positive for reducing substances in the 
urine should undergo formal genetic testing. These babies should also be managed with high 
carbohydrate, low fat diets and not allowed to fast for more than four hours2,52. 
Thus, AFLP represents a rare, treatable and reversible cause of acute liver failure, with prompt 
and complete recovery after early recognition and emergent delivery. 
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Materials and Methods 
 
Case finding :  
We found the cases by collecting all the patients who underwent liver biopsies for acute 
liver failure in the third trimester of pregnancy during the period 1998 to 2006. The hospital 
records of these patients were studied. Data abstracted from the records included the parameters 
needed for clinical diagnosis, time of admission to hospital, time of delivery of the baby and time 
of liver biopsy. Patients with incomplete data were excluded. 
For negative disease controls, we collected as many cases as we could of those with acute liver 
failure where a definite etiological agent was discovered by tests other than biopsy. By this we 
assumed that AFLP was excluded in them. 
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Figure 1. : Flow chart depicting the patients in the various groups of the study. 
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Methods of classification :  
Patients were classified into three groups.  
Group A- Those in whom the biopsy was consistent with AFLP. These were patients who 
had to have a completely negative investigative work-up for other etiologies before liver biopsy 
was done. 
Group B- Those in whom a biopsy was available but the histology was inconsistent with 
AFLP. These too had a negative pre-biopsy work up. 
Group C- Those in whom a pre-biopsy investigative work up identified a cause of acute 
liver disease making biopsy irrelevant.             
Ch’ng et al4, in their study, have proposed diagnostic criteria (‘Swansea criteria’) for the 
pregnancy related liver diseases - HELLP, partial HELLP and pre-eclamptic liver dysfunction 
besides AFLP. The criteria for AFLP are enumerated in Table 1.  
The patients in group A were classified according to these criteria. Patients in group B – where 
the histology was inconsistent - were also classified by these criteria into AFLP, HELLP, Partial 
HELLP or pre-eclamptic liver dysfunction. Patients in group C were defined by etiological 
agents identified by blood tests and any histology available was noted but not used in reaching an 
etiological conclusion.  
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AFLP(numbers in parentheses indicate freq. in study group ) 
Presence of ≥ 6 of the following in absence of alternate explanation : 
 Vomiting (11/21) 
 Abdominal pain (3/14) 
 polydipsia/polyuria (1/1) 
 Encephalopathy (9/24) 
 Elevated bilirubin (24/24) 
 Hypoglycemia (6/20) 
 Hyperuricemia (8/10) 
 Leucocytosis (20/23) 
 Ascites or bright liver on USG* (15/21) 
 Elevated transaminases (23/24) 
 Renal impairment (15/24) 
 Coagulopathy (23/24) 
 Micro-vesicular steatosis on biopsy (17/24) 
 
 
‘*’- 3 patients had USG after delivery. 
Table 1. Proportion of patients in the study group meeting the criteria laid down by Ch’ng et al4.  
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Histology :  
The biopsies were reviewed by a single hepatopathologist unaware of the diagnosis based 
on the Swansea criteria and various findings were noted. The biopsies were classified as 
consistent with acute fatty liver of pregnancy, if it showed diffuse micro-vesicular steatosis with 
vacuolation and ballooning.  
 
Statistical Methods:  
The data was analyzed using SPSS version 15. Non-parametric tests were used to test 
significance of the continuous variables in between the three groups. Two-tailed Fischer’s exact 
test was utilized to test the significance between discrete variables. Using liver histology as the 
gold standard for the diagnosis of acute fatty liver of pregnancy, the performance of the clinical 
diagnostic criteria was assessed in three groups: groups A - where histology was diagnostic, 
group B - where histology was inconsistent or non diagnostic and group C - where tests other 
than biopsy defined an alternative diagnosis. The sensitivity and specificity were calculated 
using standard formulae. 
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Results  
 
The results are displayed in 2 parts – Initial part pertaining to testing the accuracy of 
Swansea criteria for AFLP, and the later part giving a detailed description of the study group 
characteristics.  
 
Testing the accuracy of Swansea criteria 
Patients :  
Figure 1 illustrates the derivation of the three groups. A total of 33 patients underwent 
liver biopsy for the clinical indication of pregnancy related liver disease. Patients with 
incomplete data, or alternative explanation of their clinical syndrome were excluded, and finally, 
24 patients constituted the study group (Figure 1.) 
The presence and prevalence of various individual elements of the Swansea criteria is depicted in 
Table 1.  
Classification :  
Group A: Of these 24 patients, 17 patients had biopsy confirmed acute fatty liver of 
pregnancy. The clinical features, laboratory parameters, imaging, management and course and 
outcome in these patients were noted. 
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Group B : 7/24 patients had an indeterminate histology and constituted Group B. The 
histology features in these patients are described. 
Group C : 11 patients with a defined etiology of liver failure in third trimester of 
pregnancy, were studied. The group was utilized to calculate the performance of the diagnostic 
criteria. 
 
Assessing the accuracy of Swansea criteria to diagnose AFLP : 
  Of the 24 study patients, 17 (71%) had a liver biopsy consistent with AFLP and all these 
patients fulfilled the clinical diagnostic criteria. These patients constituted Group A.  
4/11 control patients (Group C – i.e patients with definite etiology other than AFLP) had the 
presence of criteria for diagnosis of acute fatty liver of pregnancy. The table for calculation of 
sensitivity and specificity is shown (Table 2.).  
29 
 
 
 
Swansea criteria 
satisfied for AFLP 
Swansea criteria not 
satisfied for AFLP 
Total 
Patients with 
confirmed AFLP 
(Group A- Cases) 
17 0 17 
Patients with definite 
other etiology 
(Group C- Controls) 
4 7 11 
  Total 28 
 
Table  2. : Calculation of sensitivity and specificity of the Swansea criteria vis-à-vis liver biopsy. 
 
 
 
 
With histological confirmation and negative etiological work-up as the gold standard for 
diagnosis of AFLP, sensitivity and specificity of the clinical diagnostic criteria were thus 100% 
and 64% respectively. Positive and negative predictive values were 81% and 100% respectively. 
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Performance of Swansea criteria in Group B : 
3/ 7 patients in group B fulfilled the Swansea criteria for the diagnosis of AFLP, but the 
histology showed only non-specific findings. Thus, of the 20 patients in the study group who 
fulfilled Swansea criteria for the diagnosis for AFLP, 3 patients had biopsy which was not 
consistent with the diagnosis.  
AFLP being rapidly reversible syndrome after delivery, the histology findings may reverse if 
there is delay in obtaining a liver biopsy. There was no significant difference in the two groups 
as far as the delay in liver biopsy is concerned (Group A- 4.4 ± 2.4 days v/s Group B - 5.9 ± 2.8 
days; p-value : 0.18). 
On analyzing patients with Swansea criteria positive for AFLP (20 patients), there was a trend to 
non-confirmatory biopsies with increase in the interval between delivery and liver biopsy (> 5 
days, 2/9), while biopsies taken <5 days after delivery were more likely to be confirmatory 
(10/11). This difference also was not significant. 
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Detailed description of the features in patients with pregnancy related liver 
disease - study group (N=24) 
The second part of the study entailed description of the features in patients with 
confirmed AFLP (Group A) and possible differences between different groups.  
The study group consisted of 24 patients with acute liver failure in 3rd trimester of pregnancy and 
all etiologic work-up negative. Among them, 5 patients had post-mortem per-cutaneous liver 
biopsy, and the rest had post–natal biopsies via the trans-jugular route. The trans-jugular liver 
biopsies were performed as soon as the clinical condition of the patient permitted the procedure.  
The median time between delivery and liver biopsy was 4 days (range 1-11 days).  The majority 
(71%) of the study patients had diffuse hepatic micro-vesicular steatosis, consistent with acute 
fatty liver of pregnancy, and same was true for the complete cohort of 33 patients who 
underwent liver biopsy. Biopsy findings in the patients are summarized in Table 3. 
Based on the criteria proposed by Ch’ng et al4, there was a considerable overlap between the 
various syndromes; which is highlighted in Table 4.  
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Liver biopsy findings 
 
Study Group * 
N = 24 
All patients with pregnancy 
related disease who underwent 
liver biopsy* 
N= 33 
Diffuse micro-vesicular 
steatosis 
17 (71%) 
 
25 (76%) 
Bridging necrosis 1 (4%) 1 (3%) 
Predominant 
hepatocanalicular 
cholestasis 
2 (8%) 2 (6%) 
Congestion with 
centrilobuar necrosis 
 
2 (8%) 2 (6%) 
Predominant cholestasis 
with mild inflammation 
1 (4%) 1 (3%) 
Predominant cholestasis 
with mild micro-vesicular 
steatosis 
- 1 (3%) 
Non-specific changes 1 (4%) 1 (3%) 
‘*’ – Number (percentage) 
Table 3. : Liver biopsy findings in the study group, and also in all patients who had biopsy for 
suspected pregnancy related liver disease during 1998- 2006 at Vellore. 
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Clinical Diagnoses Number (Percentage) 
AFLP 5 (22 %) 
AFLP + HELLP/ Partial HELLP 13 ( 52 % ) 
AFLP + Preeclampsia + partial HELLP 1 (4%) 
AFLP + Pre-eclampsia 1 (4%) 
HELLP Syndrome 1 (4 %) 
Partial HELLP Syndrome 1 (4 %) 
Preeclamptic liver dysfunction 1 (4 %) 
Preeclampsia + HELLP 1 (4 %) 
 
Table 4. : Syndromic diagnoses in the study group (n= 24) 
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Clinical features in patients with confirmed AFLP (Group A; n=17) : 
Patients ranged from 20 – 28 yrs (mean - 23 ± 3 years) and the majority -11 (65%) was 
primigravida. The mean gestational age was 37 weeks (Range 33 – 40 weeks). 3/17 (18%) 
patients were delivered elsewhere before being referred for further management. 12 of the 14 
patients who had delivery at our institute were delivered within the 1st 24 hours and rest within 
36 hours, with a median delay of 7 days (Range 1-15 days) from the onset of symptoms. 
Apart from jaundice (100%), other common presenting symptoms were pedal edema (65%), 
bleeding manifestations (41%), encephalopathy (35%), ascites (41%) and vomiting (59%). Less 
common symptoms were fatigue (18%), polyuria (6%) and polydipsia (6%). Approximately, a 
quarter of the AFLP patients had hypertension. None of the patients had a prior or a family 
history of similar liver disease in pregnancy. Fetal distress was noted in 59% (Table 5). 
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Group 
A 
(n=17) 
Group 
B 
(n=7) 
Group 
C 
(n=11) 
Group A v/s 
Group B 
(p-value) 
Group A v/s 
Group C 
(p-value) 
Age of the patient (years) 22.9±2.6 23.3±4.4 27.5±5.4 0.77 0.03 
Clinical 
presentation 
Jaundice 17 7 11 1.0 1.0 
Vomiting 10 1 7 0.08 1.0 
Polydipsia/ 
polyuria 
1 0 0 1.0 1.0 
Ascites 7 3 5 1.0 1.0 
Pedal edema 11 6 5 0.6 0.4 
Encephalopathy 6 3 2 1.0 0.4 
Bleeding 7 2 1 0.67 0.1 
Fatigue 3 1 0 1.0 0.26 
Fever 7 0 4 0.07 1.0 
Discharge p/v 1 1 0 0.51 1.0 
Seizures 0 1 0 0.29 1.0 
Fetal distress 10 3 2 0.66 0.05 
Duration of symptoms (days) 5.9±3.9 4.3±4.9 4.9±3.4 0.21 0.51 
Gravida (1/2/3/>3) 11/4/2/0 6/1/0/0 3/4/1/3 0.51 0.28 
Weeks of pregnancy 36.9±2.2 32.4±7.1 33.7±2.8 0.26 0.01 
 
Table 5. : Demographics and mode of presentation in different groups of the study 
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Laboratory parameters and imaging studies in confirmed AFLP patients (Group A; n=17): 
The mean values, standard deviation and range of the initial laboratory tests performed is 
shown in Table 6.  
On ultrasound examination, 18% had a normal liver and no ascites, while 53% had ascites, 12% 
had a fatty liver and 6% had shrunken liver. The various radiological findings are given in Table 
7. 
Histology in confirmed AFLP patients (Group A; n=17) : 
The biopsy findings of all patients are summarized in Table 3.  
In 17 patients with confirmed AFLP according to the diagnostic criteria and histology, 
the biopsy findings besides diffuse/ perivenular  micro-vesicular steatosis or ballooning, were - 
mild hepatocanalicular cholestasis (15/17), foci of extramedullary hematopoiesis (8/17), mild 
portal and lobular inflammation (16/17), regeneration (7/17), presence of ceroid bodies (5/17) 
and minimal necrosis (3/17). 
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Parameters Group A (mean±SD) 
Group B 
(mean±SD) 
Group C 
(mean±SD) 
Group A v/s 
Group B 
(p-value) 
Group A v/s 
Group C 
(p-value) 
S. Bilirubin 
(mg%) 
13.0±3.7 12.1±10.4 9.4±8.0 0.099 0.02 
Direct Bilirubin 
(mg%) 
10.8±3.4 9.7±9.0 7.4±6.4 0.81 0.02 
S. Protein (g%) 5.0±0.9 4.8±0.8 5.6±1.0 0.85 0.19 
S. Albumin (g%) 2.1±0.3 2.2±0.3 2.2±0.7 0.49 0.78 
AST (U/L) 146.1±89.0 3645±9341 393.7±433.5 0.62 0.55 
ALT (U/L) 129.3±76.3 266.7±480.1 238.5±229.4 0.31 0.49 
ALP (U/L) 475.9230.3 298.7±164.1 383.6±260.6 0.05 0.29 
LDH (U/L) 1166.6±496.2 1454.3±915.3 787.9±319.2 0.49 0.04 
PT (seconds) 39.0±26.7 38.76±39.2 31.1±22.5 0.35 0.19 
aPTT (seconds) 88.1±49.7 66.1±52.6 63.4±47.0 0.19 0.08 
Fibrinogen (mg%) 103.5±18.5 76.9±46.2 198.7±262.1 0.67 0.64 
S. Creatinine 
(mg%) 
1.74±0.82 1.7±1.09 1.05±0.34 0.58 0.01 
MELD 32.1±6.7 29.6±10.9 23.7±12.1 0.534 0.13 
Uric Acid (mg%) 7.0±0.7 7.6±0.4 6.6±7.8 0.17 0.07 
Hb (g%) 14.6±19.2 10.7±2.3 9.8±3.0 0.66 0.58 
Total count 
(x103percmm) 
20.2±7.3 19.7±9.3 19.3±8.4 0.92 0.82 
Platelets 
(x105percmm) 
1.24±0.58 0.80±0.57 1.82±0.97 0.08 0.07 
 
Table 6. : Laboratory parameters in patients in different groups  
38 
 
 
 
USG abdomen Total 
Normal Ascites Fatty liver Volume redistribution Not done Normal
Groups 
Group A 3 9 2 1 2 17 
Group B 2 4 0 0 1 7 
Group C 5 4 1 0 1 11 
Total 10 17 3 1 4 35 
 
Table 7. : Radiological features in different groups of the study. 
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Course and Outcome in confirmed AFLP patients (Group A; n=17) :  
2 (12%) of the mothers and 5 (29%) of the babies had a fatal outcome. The outcome is 
depicted in Table 8. 
The mean stay in hospital was 11 ± 4 days (Range 1- 19 days) and an average of 18 ± 15 blood 
products were administered per patient. Among the 17 AFLP patients, 9 were delivered by 
Caesarean section and others by vaginal route. 12/17 babies were male and 3 were twins. The 
details are shown in Table 9. 
Biochemical parameters, mode of delivery, sex of the baby and time delay of delivery from onset 
of symptoms and from admission did not have any influence on the maternal and fetal outcome 
in this group of patients. 
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Group 
A 
Group 
B 
Group 
C 
Group A 
v/s Group B  
(p-value) 
Group A 
v/s Group 
C  
(p-value) 
Adverse maternal outcome 
(Death) 
2 3 4 0.09 0.12 
Adverse fetal outcome (IUD/ Still 
birth/ Death immediately after 
birth) 
5 3 2 0.59 0.92 
 
Table 8. : Outcome of the patients in different groups of the study. 
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Group 
A 
Group 
B 
Group 
C 
Group A v/s 
Group B  
(p-value) 
Group A v/s 
Group C  
(p-value) 
Hospital stay (days) 11±4 10±6 13±5 0.95 0.49 
Blood products required 18±15 16±19 8±9 0.41 0.06 
Mode of delivery 
(Vaginal/Caesarean) 
8/9 4/3 5/3* - - 
Sex of the child 
(Male/Female/Twins) 
12/2/3 3/4/0 2/2/0*  - - 
 
‘*’ – Data not complete 
Table 9. : Course of the patients in different groups of the study. 
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Characteristics of the patients in Group B (n=7) :  
Of the 24 study patients, who had no etiology for the acute liver failure, 7 had an 
histology which was not consistent with acute fatty liver of pregnancy.  
The demographics, mode of presentation, laboratory parameters, radiologic features, maternal 
and child outcome and course are noted in Table 6, Table 7, Table 8, Table 9 and Table 10 
respectively. The details of the histology in these patients are noted in Table 2. It was very 
similar to Group A in all characteristics and final outcome. 
 
Control Group (Group C) : 
The control group consisted of 11 patients having jaundice complicating third trimester of 
pregnancy, with a well defined etiology. The etiology of liver dysfunction in these patients was - 
acute hepatitis E (6 patients), acute hepatitis A and B (1 patient each), scrub typhus (1 patient), S. 
paratyphi infection (1 patient) and malaria (1 patient).   
The demographics, mode of presentation, laboratory parameters, radiologic features, maternal 
and child outcome and course are noted in Table 6, Table 7, Table 8, Table 9 and Table 10 
respectively. As compared to group A, patients in group C were older, presented earlier in the 
course of pregnancy and had a lower S. bilirubin and S. Creatinine. The outcome though, was 
similar in both the groups. 
Of these 11 patients, 4 fulfilled the diagnostic criteria for acute fatty liver of pregnancy. These 4 
patients, who fulfilled diagnostic criteria, had a significantly higher MELD score (36 v/s 17; p-
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value – 0.02), S. bilirubin (16.6 v\s 5.3; p-value 0.01) and prothrombin time (52.5 v/s 18.9; p-
value – 0.04). Though not attaining stastical significance, maternal mortality was higher in these 
4 patients (2/4; 50%) as compared to the others (2/7; 29%). Thus the diagnostic criteria, if 
applied to this group of patients, identified a sicker individual. 
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Discussion 
 
 
Acute fatty liver of pregnancy is a relatively rare but serious occurrence1. The importance 
of early recognition and timely management of AFLP derives from the improvement in maternal 
and fetal outcomes with early delivery of the fetus1,2,3.  
There have been only a few case reports pertaining to the disease from this part of the world6. 
Contrary to the recently published data on acute liver failure in pregnancy13, this case series 
illustrates the presence of acute fatty liver of pregnancy as an important cause of acute liver 
failure in pregnancy in south India. 
A liver biopsy is considered to be the gold standard in the diagnosis of this condition2,3, but is 
usually not possible or is delayed due to coagulopathy or ascites. Decisions on termination of 
pregnancy are usually based on clinical features and basic laboratory parameters.  Diagnostic 
criteria were proposed by Ch’ng et al4 based on retrospective case series. There was a large 
prospective study comparing the performance of these ‘Swansea criteria’ against clinical 
judgment. This showed considerable agreement between the two methods5. The downside of it 
was the absence of the gold standard diagnostic test – liver biopsy. The accuracy of these criteria 
in diagnosing biopsy confirmed acute fatty liver of pregnancy has not been studied so far. This is 
a largest case series till date, correlating clinical findings with biopsy proven acute fatty liver of 
pregnancy.  
45 
 
In our study, patients in the 3rd trimester of pregnancy who underwent liver biopsy for a probable 
clinical diagnosis of pregnancy related liver diseases were included. Among them, 76% had 
histology findings consistent with a diagnosis of acute fatty liver of pregnancy, but 2 patients 
with micro-vesicular steatosis on liver biopsy, were found later to also test positive for IgM anti-
hepatitis E antibody. These findings indicate either a concomitant acute hepatitis E infection 
(more likely) or the possibility that though liver biopsy is the best available test for acute fatty 
liver disease, it may not always be diagnostic. The vomiting and anorexia, secondary to acute 
viral hepatitis may be a precipitating event for AFLP. But for the sake of avoiding confusion, the 
patients in whom viral markers were not tested were excluded from the analysis, in order to have 
complete laboratory and clinical details to enable comparison of biopsies with clinical findings.  
However, among the 24 patients where the data was complete, there was a considerable overlap 
in these syndromic diagnoses with 67% patients satisfying clinical criteria for more than one 
condition (Table 4).  
Commonly occurring elements of the criteria, in the study group, for the syndromic diagnosis of 
acute fatty liver of pregnancy were – jaundice (100%), coagulopathy (96%), elevated 
transaminases (96%), leucocytosis (87%), altered renal functions (63%) and ultrasound 
abnormalities (71%) (Table 1).  Patients who had diffuse micro-vesicular steatosis (Group A) 
were similar to the patients with other non-specific findings on liver biopsy (Group B); as far as 
routine biochemical tests, duration of hospital stay, requirement of blood products and maternal 
and fetal outcome, were concerned.  
Contrary to a recent study by Devarbhavi et al9, maternal and fetal mortality in our patients was 
considerably lower (41% and 53% v/s 12% and 29%). S. bilirubin, S. creatinine, total WBC 
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count or prothrombin time was not significantly different in patients who expired than in others 
with a favorable outcome. As only 2 patients expired, predictors of mortality could not be 
studied adequately. 
The criteria for diagnosis of AFLP, was fulfilled in 100% patients in group A and also in 1/3rd of 
patients with defined etiology of liver dysfunction (Group C). The sensitivity and specificity of 
the diagnostic criteria for acute fatty liver of pregnancy, was 100% and 64% respectively. 
Negative predictive value was 100%. Considering the high maternal and fetal mortality in this 
condition, the diagnostic criteria remain relevant despite their low specificity. These criteria have 
a very high negative predictive value, ensuring no patient with this condition is missed. On the 
other hand, this may lead to over diagnosis.   
There is a high false positive rate, which makes it an inappropriate research tool. The gold 
standard for diagnosis of acute fatty liver of pregnancy is still the combination of a negative 
etiology workup and a consistent histology. The use of liver biopsy as a clinical tool for 
diagnosis may not be needed, as the negative predictive value for the Swansea criteria was 
100%.  
As the diagnostic criteria for AFLP are satisfied in a proportion of patients with other defined 
etiology, the use of these criteria in an emergency setting without concomitant diagnostic workup 
is fraught with a danger of over diagnosis. This may be difficult in a lesser equipped center 
where the serology tests either may not be available promptly or the processing is delayed9. In 
this group C, the Swansea criteria were helpful in identifying a patient with comparatively severe 
disease with a consequently higher chance of mortality. Whether these patients benefit from 
early termination of pregnancy is still debatable. 
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The retrospective nature of the study and arbitrary derivation of Group C, are the major 
limitations of the study. Even though this is the largest case series of AFLP from India, the 
mortality predictors could not be studied, due to small sample size.  
A prospective study with detailed clinical, laboratory and histology data will help elucidate the 
true validity of the clinical diagnostic criteria, but our results on 24 patients indicate that the 
clinical diagnostic criteria proposed by Ch’ng et al4, are an accurate and early means to diagnose 
this dangerous but eminently treatable condition. An early post-partum biopsy may help in 
confirmation of the diagnosis.   
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Summary 
 
1. This is the largest study to date, comparing the diagnostic criteria (Swansea criteria) for 
AFLP against the gold standard – Liver biopsy. 
2. Swansea criteria had a sensitivity of 100% and a negative predictive value of 100% in 
diagnosing AFLP, making it a good clinical test. It excludes the possibility of AFLP. 
3. Swansea criteria for AFLP had a poor specificity (64%) and poor positive predictive 
value rendering it an inadequate test to diagnose AFLP in research setting.  
4. In patients with definite other etiology of acute liver failure, Swansea criteria were able to 
distinguish a sicker patient with higher chance of mortality. Whether these patients will 
benefit from early termination of pregnancy is still debatable. 
5. Mean age of the patients with confirmed AFLP was 23 ± 3 years and the majority -11 
(65%) was primigravida. The mean gestational age was 37 weeks (Range 33 – 40 weeks) 
6. Jaundice and vomiting were the most common presenting symptoms for AFLP. The 
presentation was similar in all the groups. 
7. The mean MELD of the patients of AFLP was 32.1±6.7. This was similar in all the 
groups.  
8. 12/17 patients with AFLP had an abnormal USG abdomen.  
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9. Due to a considerable overlap - clinical features, laboratory parameters and radiologic 
features were not helpful in differentiating AFLP from the patients with other defined 
etiology. 
10. In patients with AFLP, mean stay in hospital was 11 ± 4 days and an average of 18 ± 15 
blood products were administered per patient.  
11. 9/17 patients with AFLP were delivered by Caesarean section and others by vaginal 
route. 
12. Majority of the babies born to AFLP patients were male (12/17). 3 were twins.  
13. 2 (12%) of the mothers and 5 (29%) of the babies had a fatal outcome in patients with 
AFLP, which was not different from the other groups. Due to small sample size, 
predictiors of maternal mortality could not be well studied. 
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Appendix 
Proforma 
 
Name :       IP No. : 
Age :       Rural/ Urban : 
Religion :       
Trimester :      Gravida :  
Weeks of pregnancy : 
Date of admission :     Date of discharge : 
Liver Bx. No. :      Date of liver biopsy : 
Symptoms 
Duration of symptoms before presentation : 
Symptoms at presentation (Jaundice, vomiting etc) 
P/H of similar complaints :    F/H of similar complaints : 
H/O regular ANC : 
Signs 
BP : 
Fetal distress : 
Investigations 
LFTs (total bilirubin. Direct bilirubin, S. protein, S. albumin, AST, ALT, ALP) 
PT (INR)      aPTT 
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Fibrinogen 
CBC (Hb, TC, DC, Platelets)     S. Creatinine 
Plasma Ammonia     Blood sugars 
S. Uric acid      S. LDH 
HCV antibody      HBsAg 
IgM HEV      IgM HAV 
p/s MP 
Blood C/S      Urine C/S 
Urine albumin 
 
USG abdomen : 
 
Liver biopsy findings : 
 
 
Outcome 
Mode of delivery : 
Blood products required : 
Sex of the child : 
 
Maternal outcome :  
Child outcome : 
 
